Embryonic, Fetal, and Neonatal Complications in Infants of Diabetic Mothers: Insights from the Cincinnati Diabetes in

Francis B Mimouni1, Jane C Khoury2,3,4, Shelley Ehrlich2,3,5

  • 1Department of Pediatrics and Research Institute, Leumit Health Services, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

PubMed

Insights

Strict glycemic control is crucial for infants of diabetic mothers (IDMs). Poor control during embryogenesis increases congenital malformations, while third-trimester control impacts macrosomia and neonatal complications.

Area of Science:

  • Perinatology
  • Neonatology
  • Endocrinology

Background:

  • Infants of diabetic mothers (IDMs) face significant risks for congenital malformations and neonatal complications.
  • The Cincinnati Diabetes in Pregnancy Program Project Grant (PPG) has extensively studied these risks.

Purpose of the Study:

  • To review the PPG's contributions to understanding glycemic control's impact on embryonic, fetal, and neonatal outcomes in IDMs.
  • To identify specific risks associated with different pregnancy stages and glycemic control levels.

Main Methods:

  • Retrospective review of PPG research data.
  • Analysis of associations between maternal glycemic control, maternal factors, and various infant complications.

Main Results:

  • Poor glycemic control during embryogenesis is a key risk for major congenital malformations (CMs); maternal magnesium deficiency is also implicated.
  • Macrosomia is linked to third-trimester poor glycemic control and maternal insulin antibodies crossing the placenta.
  • Neonatal hypoglycemia correlates with third-trimester glycemic control and labor hyperglycemia.
  • Modern care minimizes Respiratory Distress Syndrome (RDS) risk; asphyxia and polycythemia are linked to maternal hyperglycemia and poor late-pregnancy glycemic control.

Conclusions:

  • Glycemic control throughout pregnancy, including labor, is vital for reducing fetal and neonatal morbidity in diabetic pregnancies.
  • Strict maternal glycemic management is essential for improving outcomes for infants of diabetic mothers.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
911
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
521
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
247